Advertisement

Topics

Sarepta licenses Pompe program from Lacerta, options two CNS candidates

15:40 EDT 10 Aug 2018 | Elsevier Business Intelligence

Sarepta Therapeutics Inc. licensed exclusive worldwide rights to Lacerta Therapeutics Inc.'s gene therapy candidate for Pompe...

Original Article: Sarepta licenses Pompe program from Lacerta, options two CNS candidates

NEXT ARTICLE

More From BioPortfolio on "Sarepta licenses Pompe program from Lacerta, options two CNS candidates"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...